Merck & Company (MRK) 56.11 $MRK
Merck's Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus(R)
BusinessWire - Mon Jun 13, 9:30AM CDT
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from two Phase 3 studies evaluating MK-1293, Merck's investigational, follow-on biologic* insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes. In both studies, MK-1293 achieved its primary endpoint by demonstrating non-inferiority in change from baseline A1C (a measure of average blood glucose) and similar safety to Lantus(R) (insulin glargine)** after 24 weeks in patients with type 1 and type 2 diabetes. Furthermore, in both studies, MK-1293 met its pre-specified secondary efficacy endpoints of statistical A1C equivalence to Lantus, a measure used to show that an investigational treatment is similar, within an acceptable range, to a current therapy.
MRK: 56.11 (-0.70)
Merck (MRK) Crosses Pivot Point Support at $56.56
Comtex SmarTrend(R) - Mon Jun 13, 9:14AM CDT
Merck (NYSE:MRK) has opened bearishly below the pivot of $56.82 today and has reached the first level of support at $56.56. Should the shares continue to fall, the support pivots of $56.31 and $55.80 will be of interest.
MRK: 56.11 (-0.70)
Pfizer Reveals Final Phase III Data on Inotuzumab Ozogamicin
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 7:50AM CDT
Pfizer (PFE) announced final data from the phase III study on inotuzumab ozogamicin for the treatment of relapsed/refractory acute lymphoblastic leukemia.
ANIP: 53.19 (+1.14), MRK: 56.11 (-0.70), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
Merck in Agreement with HAPPYneuron to Offer First-of-its-Kind e-Health Solution for People Living with Multiple Sclerosis
PR Newswire - Mon Jun 13, 2:00AM CDT
-- Agreement provides Merck with exclusive license to cognitive remediation training programs
MRK: 56.11 (-0.70)
Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
BusinessWire - Sat Jun 11, 10:00AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE
FE), today announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily). These results from the VERTIS clinical development program of ertugliflozin will be presented for the first time at the 76th Scientific Sessions of the American Diabetes Association, which are being held in New Orleans from June 10-14, 2016.
PFE: 34.74 (-0.55), MRK: 56.11 (-0.70)
Merck Becomes #15 Most Shorted Dow Stock, Replacing General Electric
MarketNewsVideo.com - Fri Jun 10, 9:59AM CDT
The most recent short interest data has been released for the 05/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover."...
MRK: 56.11 (-0.70)
Merck (MRK) to Acquire Afferent in Deal Worth Up To $1.25B
Arpita Dutt - Zacks Investment Research - Fri Jun 10, 7:53AM CDT
Merck's (MRK) upcoming acquisition of biotech company Afferent will add a mid-stage chronic cough candidate to its pipeline.
JNJ: 116.79 (-0.22), MRK: 56.11 (-0.70), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
Merck to buy biotech drug developer Afferent Pharmaceuticals
By The Associated Press - AP - Thu Jun 09, 5:34PM CDT
KENILWORTH, N.J. (AP) — Drugmaker Merck is buying Afferent Pharmaceuticals, a privately held biotechnology company developing a chronic cough medication.
MRK: 56.11 (-0.70)
Merck to Acquire Afferent Pharmaceuticals
BusinessWire - Thu Jun 09, 5:34PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this privately held pharmaceutical company. Afferent Pharmaceuticals is a leader in the development of therapeutic candidates targeting the P2X3 receptor for the treatment of common, poorly-managed, neurogenic conditions. Afferent's lead investigational candidate, AF-219, is a selective, non-narcotic, orally-administered P2X3 antagonist currently being evaluated in a Phase 2b clinical trial for the treatment of refractory, chronic cough as well as in a Phase 2 clinical trial in idiopathic pulmonary fibrosis (IPF) with cough.
MRK: 56.11 (-0.70)
Organovo Announces Fiscal Fourth-Quarter and Full-Year 2016 Results; Company Issues Full-Year Fiscal 2017 Outlook
GlobeNewswire - Thu Jun 09, 3:05PM CDT
Organovo Holdings, Inc. (NYSE MKT:ONVO) ("Organovo"
, a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today reported financial results for the fiscal fourth quarter of 2016, issued its full-year fiscal 2017 outlook and affirmed its long-range guidance. Net loss was $8.4 million, or $0.09 per share, for the fiscal fourth quarter of 2016, as compared to $7.8 million, or $0.10 per share, for the fiscal fourth quarter of 2015.
ONVO: 2.89 (-0.21), MRK: 56.11 (-0.70)
Agenus Announces Lead Product Candidate Selection in its Collaboration with Merck
BusinessWire - Thu Jun 09, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators (CPMs) and cancer vaccines, today announced the selection of a lead product candidate under its license and research collaboration with Merck. Merck, known as MSD outside the United States and Canada, has selected a lead antibody candidate and several backup antibodies, discovered by Agenus, to an undisclosed Merck checkpoint target. Based on this milestone and under the terms of the agreement, Agenus received a $2 million milestone payment from Merck.
AGEN: 4.00 (unch), MRK: 56.11 (-0.70)
Consumer Health To Play A Pivotal Role In Merck's Africa Growth Strategy
CNW Group - Thu Jun 09, 4:02AM CDT
Merck, a leading science and technology company, today outlined the role its Consumer Health business will play within the company's new Africa growth strategy. Merck, which has been delivering healthcare services in Africa since 1897, unveiled an ambitious objective to more than double sales in Africa to about € 500 million by 2020, during an Executive Board visit to ten African countries in November 2015. As part of this strategy, 2016 will be a year of investment in selected African countries for Merck's Consumer Health business. Among others, the company plans to focus on its well-known global strategic brands such as Seven Seas(®), Nasivin(®) and Neurobion(®) on the continent. Focusing on innovation and access to health, Merck's Consumer Health business is expected to play a pivotal role in Merck's commitment to supporting healthy families, healthy communities and healthy economies in Africa.
MRK: 56.11 (-0.70)
Don’t Get Caught With These 5 Stocks Ahead of Earnings Season
ESTMZ - Wed Jun 08, 3:01PM CDT
First quarter earnings season is coming to an end with the earnings recession still deeply entrenched in the market’s memory. Almost all S&P 500 companies have reported and results have been largely disappointing. This marked the first time the...
AA: 9.32 (-0.17), GS: 148.63 (-1.26), GILD: 83.98 (-0.47), MRK: 56.11 (-0.70), CMG: 394.00 (-11.26), GPS: 18.91 (-0.01), AAPL: 97.34 (-1.49)
NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and NASH
PR Newswire - Wed Jun 08, 8:00AM CDT
NGM Bio, a privately-held biotechnology company that translates powerful biology into transformative medicines, today reported initiation of a Phase 1 trial of NGM313 in overweight or obese volunteers. NGM313 is an agonistic antibody engineered to selectively activate the beta-klotho (KLB)-FGFR1c receptor complex and promote beneficial metabolic activity. NGM313 was discovered and is being developed by NGM Bio as a potential treatment for type 2 diabetes, obesity and nonalcoholic steatohepatitis (NASH). Under the terms of a collaboration agreement with Merck Sharp and Dohme Corp. ("Merck" executed in 2015, Merck has an exclusive, one-time option to license NGM313 following completion of a human proof of concept study.
MRK: 56.11 (-0.70)
Cystoid Macular Edema Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Allergran, Merck, Bayer - Research and Markets
BusinessWire - Wed Jun 08, 6:11AM CDT
Research and Markets has announced the addition of the "Cystoid Macular Edema Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
MRK: 56.11 (-0.70)
Chemotherapy Induced Nausea & Vomiting Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Merck, Tesaro, Eisai - Research and Markets
BusinessWire - Wed Jun 08, 4:36AM CDT
Research and Markets has announced the addition of the "Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
MRK: 56.11 (-0.70)
Fish & Richardson Obtains Reversal of $200 Million Patent Verdict Against Gilead After Merck's "Pervasive Pattern of Misconduct"
Marketwire Canada - Tue Jun 07, 4:07PM CDT
Judge Finds Merck Forfeited Its Right to Assert Patents Against Gilead Because of "Unclean Hands" and "Numerous Unconscionable Acts"
MRK: 56.11 (-0.70)
Merck's Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus(R)
BusinessWire - Mon Jun 13, 9:30AM CDT
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from two Phase 3 studies evaluating MK-1293, Merck's investigational, follow-on biologic* insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes. In both studies, MK-1293 achieved its primary endpoint by demonstrating non-inferiority in change from baseline A1C (a measure of average blood glucose) and similar safety to Lantus(R) (insulin glargine)** after 24 weeks in patients with type 1 and type 2 diabetes. Furthermore, in both studies, MK-1293 met its pre-specified secondary efficacy endpoints of statistical A1C equivalence to Lantus, a measure used to show that an investigational treatment is similar, within an acceptable range, to a current therapy.
MRK: 56.11 (-0.70)
Merck (MRK) Crosses Pivot Point Support at $56.56
Comtex SmarTrend(R) - Mon Jun 13, 9:14AM CDT
Merck (NYSE:MRK) has opened bearishly below the pivot of $56.82 today and has reached the first level of support at $56.56. Should the shares continue to fall, the support pivots of $56.31 and $55.80 will be of interest.
MRK: 56.11 (-0.70)
Pfizer Reveals Final Phase III Data on Inotuzumab Ozogamicin
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 7:50AM CDT
Pfizer (PFE) announced final data from the phase III study on inotuzumab ozogamicin for the treatment of relapsed/refractory acute lymphoblastic leukemia.
ANIP: 53.19 (+1.14), MRK: 56.11 (-0.70), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
Merck in Agreement with HAPPYneuron to Offer First-of-its-Kind e-Health Solution for People Living with Multiple Sclerosis
PR Newswire - Mon Jun 13, 2:00AM CDT
-- Agreement provides Merck with exclusive license to cognitive remediation training programs
MRK: 56.11 (-0.70)
Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
BusinessWire - Sat Jun 11, 10:00AM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE
FE), today announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily). These results from the VERTIS clinical development program of ertugliflozin will be presented for the first time at the 76th Scientific Sessions of the American Diabetes Association, which are being held in New Orleans from June 10-14, 2016. PFE: 34.74 (-0.55), MRK: 56.11 (-0.70)
Merck Becomes #15 Most Shorted Dow Stock, Replacing General Electric
MarketNewsVideo.com - Fri Jun 10, 9:59AM CDT
The most recent short interest data has been released for the 05/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover."...
MRK: 56.11 (-0.70)
Merck (MRK) to Acquire Afferent in Deal Worth Up To $1.25B
Arpita Dutt - Zacks Investment Research - Fri Jun 10, 7:53AM CDT
Merck's (MRK) upcoming acquisition of biotech company Afferent will add a mid-stage chronic cough candidate to its pipeline.
JNJ: 116.79 (-0.22), MRK: 56.11 (-0.70), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
Merck to buy biotech drug developer Afferent Pharmaceuticals
By The Associated Press - AP - Thu Jun 09, 5:34PM CDT
KENILWORTH, N.J. (AP) — Drugmaker Merck is buying Afferent Pharmaceuticals, a privately held biotechnology company developing a chronic cough medication.
MRK: 56.11 (-0.70)
Merck to Acquire Afferent Pharmaceuticals
BusinessWire - Thu Jun 09, 5:34PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this privately held pharmaceutical company. Afferent Pharmaceuticals is a leader in the development of therapeutic candidates targeting the P2X3 receptor for the treatment of common, poorly-managed, neurogenic conditions. Afferent's lead investigational candidate, AF-219, is a selective, non-narcotic, orally-administered P2X3 antagonist currently being evaluated in a Phase 2b clinical trial for the treatment of refractory, chronic cough as well as in a Phase 2 clinical trial in idiopathic pulmonary fibrosis (IPF) with cough.
MRK: 56.11 (-0.70)
Organovo Announces Fiscal Fourth-Quarter and Full-Year 2016 Results; Company Issues Full-Year Fiscal 2017 Outlook
GlobeNewswire - Thu Jun 09, 3:05PM CDT
Organovo Holdings, Inc. (NYSE MKT:ONVO) ("Organovo"
, a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today reported financial results for the fiscal fourth quarter of 2016, issued its full-year fiscal 2017 outlook and affirmed its long-range guidance. Net loss was $8.4 million, or $0.09 per share, for the fiscal fourth quarter of 2016, as compared to $7.8 million, or $0.10 per share, for the fiscal fourth quarter of 2015. ONVO: 2.89 (-0.21), MRK: 56.11 (-0.70)
Agenus Announces Lead Product Candidate Selection in its Collaboration with Merck
BusinessWire - Thu Jun 09, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators (CPMs) and cancer vaccines, today announced the selection of a lead product candidate under its license and research collaboration with Merck. Merck, known as MSD outside the United States and Canada, has selected a lead antibody candidate and several backup antibodies, discovered by Agenus, to an undisclosed Merck checkpoint target. Based on this milestone and under the terms of the agreement, Agenus received a $2 million milestone payment from Merck.
AGEN: 4.00 (unch), MRK: 56.11 (-0.70)
Consumer Health To Play A Pivotal Role In Merck's Africa Growth Strategy
CNW Group - Thu Jun 09, 4:02AM CDT
Merck, a leading science and technology company, today outlined the role its Consumer Health business will play within the company's new Africa growth strategy. Merck, which has been delivering healthcare services in Africa since 1897, unveiled an ambitious objective to more than double sales in Africa to about € 500 million by 2020, during an Executive Board visit to ten African countries in November 2015. As part of this strategy, 2016 will be a year of investment in selected African countries for Merck's Consumer Health business. Among others, the company plans to focus on its well-known global strategic brands such as Seven Seas(®), Nasivin(®) and Neurobion(®) on the continent. Focusing on innovation and access to health, Merck's Consumer Health business is expected to play a pivotal role in Merck's commitment to supporting healthy families, healthy communities and healthy economies in Africa.
MRK: 56.11 (-0.70)
Don’t Get Caught With These 5 Stocks Ahead of Earnings Season
ESTMZ - Wed Jun 08, 3:01PM CDT
First quarter earnings season is coming to an end with the earnings recession still deeply entrenched in the market’s memory. Almost all S&P 500 companies have reported and results have been largely disappointing. This marked the first time the...
AA: 9.32 (-0.17), GS: 148.63 (-1.26), GILD: 83.98 (-0.47), MRK: 56.11 (-0.70), CMG: 394.00 (-11.26), GPS: 18.91 (-0.01), AAPL: 97.34 (-1.49)
NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and NASH
PR Newswire - Wed Jun 08, 8:00AM CDT
NGM Bio, a privately-held biotechnology company that translates powerful biology into transformative medicines, today reported initiation of a Phase 1 trial of NGM313 in overweight or obese volunteers. NGM313 is an agonistic antibody engineered to selectively activate the beta-klotho (KLB)-FGFR1c receptor complex and promote beneficial metabolic activity. NGM313 was discovered and is being developed by NGM Bio as a potential treatment for type 2 diabetes, obesity and nonalcoholic steatohepatitis (NASH). Under the terms of a collaboration agreement with Merck Sharp and Dohme Corp. ("Merck"
executed in 2015, Merck has an exclusive, one-time option to license NGM313 following completion of a human proof of concept study. MRK: 56.11 (-0.70)
Cystoid Macular Edema Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Allergran, Merck, Bayer - Research and Markets
BusinessWire - Wed Jun 08, 6:11AM CDT
Research and Markets has announced the addition of the "Cystoid Macular Edema Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
MRK: 56.11 (-0.70)
Chemotherapy Induced Nausea & Vomiting Global Clinical Trials Review, H1, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Merck, Tesaro, Eisai - Research and Markets
BusinessWire - Wed Jun 08, 4:36AM CDT
Research and Markets has announced the addition of the "Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
MRK: 56.11 (-0.70)
Fish & Richardson Obtains Reversal of $200 Million Patent Verdict Against Gilead After Merck's "Pervasive Pattern of Misconduct"
Marketwire Canada - Tue Jun 07, 4:07PM CDT
Judge Finds Merck Forfeited Its Right to Assert Patents Against Gilead Because of "Unclean Hands" and "Numerous Unconscionable Acts"
MRK: 56.11 (-0.70)
